Possible nonspecific immunopotentiation by 2,4-dinitrochlorobenzene sensitization in patients with Hodgkin's disease.
Various immunological parameters were evaluated in untreated Hodgkin's patients before and after sensitization with dinitrochlorobenzene (DNCB). The ratio (r) of these parameters after/before DNCB sensitization for patients and second/first samples in the controls were calculated. There were significantly more patients in the r greater than 1.1 group for PHA and Con A responses and for peripheral blood T cell percentages. These data suggest that DNCB sensitization may have a nonspecific immunopotentiation effect.
D000917:Antibody Formation / Q000187:drug effects*; D001402:B-Lymphocytes / Q000276:immunology; D003208:Concanavalin A / Q000494:pharmacology; D004137:Dinitrochlorobenzene / Q000494:pharmacology*; D006689:Hodgkin Disease / Q000276:immunology*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D008213:Lymphocyte Activation; D009578:Nitrobenzenes / Q000494:pharmacology*; D010835:Phytohemagglutinins / Q000494:pharmacology; D013268:Stimulation, Chemical; D013601:T-Lymphocytes / Q000276:immunology
D004137:Dinitrochlorobenzene; D009578:Nitrobenzenes; D010835:Phytohemagglutinins; D003208:Concanavalin A